Soralieva 200mg Tablet (Sorafenib)

The Soralieva 200mg Tablet contains sorafenib, an oral multi-kinase inhibitor used as targeted anticancer therapy. It blocks several kinases involved in tumor-cell signaling and angiogenesis, including RAF kinases and vascular endothelial growth factor receptors. Sorafenib 200mg is used in selected patients with hepatocellular carcinoma, advanced renal cell carcinoma, and differentiated thyroid carcinoma that is refractory to radioactive iodine, depending on the clinical setting and local label. It can cause hand-foot skin reaction, diarrhea, hypertension, and other significant adverse effects. Sorafenib 200mg Tablet is a prescription medicine and should be monitored by an oncologist, with attention to blood pressure, skin toxicity, liver function, bleeding risk, and potential drug interactions.

The sorafenib tablet is used for unresectable hepatocellular carcinoma in appropriate patients, advanced renal cell carcinoma, and locally recurrent or metastatic progressive differentiated thyroid carcinoma that is refractory to radioactive iodine. Its role can vary because newer systemic therapies are available for some of these diseases. The oncologist selects treatment according to tumor type, stage, previous therapy, liver function, performance status, and comorbidities. The Sorafenib 200mg Tablet is not a substitute for surgery or locoregional treatment when those options are appropriate.

Soralieva 200mg inhibits multiple kinases involved in tumor-cell proliferation and angiogenesis, including RAF kinases and VEGFR/PDGFR signaling. By interrupting both intracellular growth pathways and tumor blood-vessel formation, the sorafenib 200mg tablet can slow progression in selected liver, kidney, and thyroid cancers. VEGF-pathway blockade contributes to toxicities such as hypertension, bleeding, and wound-healing problems, while effects on skin and other tissues contribute to hand-foot skin reaction and rash.

Evidence context: The studies below are pivotal or widely cited evidence supporting the sorafenib 200mg Tablet in major treatment settings. Trial results should not be interpreted as a guarantee of benefit for an individual patient, and exact eligibility must match the current approved indication and oncology guideline.

Soralieva 200mg Tablet may cause side effects, and their frequency varies by indication, dose, combination regimen, and patient population. The list below highlights clinically important effects rather than assigning a single percentage across different trials.

Common side effects

• Hand-foot skin reaction
• Diarrhoea
• Fatigue
• Rash
• Hypertension
• Reduced appetite
• Weight loss
• Hair thinning

Serious side effects

• Severe bleeding
• Cardiac ischaemia / infarction
• GI perforation
• Severe hypertension
• Drug-induced liver injury
• Severe dermatologic reactions

The standard labelled adult dose is 400 mg orally twice daily (two 200 mg tablets per dose). Take without food or with a low- or moderate-fat meal; avoid high-fat meals around dosing because they reduce bioavailability. Dose interruption or reduction may be required for hand-foot skin reaction, hypertension, hepatic toxicity, or other significant adverse effects. The Soralieva 200 mg tablet strength does not mean the usual total daily dose is 200 mg.

Administration guidance: Take the Soralieva 200mg Tablet exactly as prescribed, commonly as a twice-daily oral regimen. It should generally be taken without food or with a low- or moderate-fat meal; avoid taking it with a high-fat meal because absorption can be altered. Swallow tablets with water. Take doses at consistent times. Blood pressure should be checked regularly, especially during the first weeks. The oncology team may interrupt or reduce the dose for hand-foot skin reaction, diarrhea, hypertension, or other toxicity. Do not change treatment without medical advice. Tell your doctor before any planned surgery because the sorafenib 200mg tablet can affect wound healing.

If a dose is missed, skip it and take the next dose at the regular time. Do not double the dose. Do not repeat a dose after vomiting.

function as clinically appropriate. Review cardiovascular history and bleeding risk. Examine skin toxicity and discuss planned surgery because treatment may need to be withheld.

Practical monitoring checklist

• Blood pressure before treatment and regularly during therapy
• Liver function according to baseline risk and treatment label
  

• FDA/EMA Nexavar (sorafenib 20mg) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021923s007lbl.pdf.
• NCCN guidelines for hepatocellular, kidney and thyroid cancers. Https://www.nccn.org/guidelines/category_1
• The new England journal of medicine. Sorafenib tablet in advanced hepatocellular carcinoma. Https://www.nejm.org/doi/full/10.1056/NEJMoa0708857.
• Asian pacific journal of cancer prevention. Efficiency and side effects of sorafenib therapy. Https://journal.waocp.org/article_28480_5c9eccb55088302296bb2e917cdf06fb.pdf.
• Journal of hepatology. Sorafenib. https://www.journal-of-hepatology.eu/article/s0168-8278(12)00440-0/fulltext​